Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T16:02:27.426Z.
Calculation as of: 2026-10-06T16:02:27.426Z.
Quote observation: 2026-10-06T15:58:55.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4f3bc52aaee10dc4864d073eee8720ed85d0d11e7a3d16422bde167dd05b99a5
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
electroCore, Inc.
Market Cap
$93.22M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$93.63M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$93.80M
Operating Cash Flow Yield
10367.13%
TTM Avg
3068.81%
3Y Avg
3068.81%
5Y Avg
3068.81%
Market Cap
$91.83M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$90.73M
Operating Cash Flow Yield
N/A
TTM Avg
23.25%
3Y Avg
23.25%
5Y Avg
23.25%
Market Cap
$89.86M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$90.54M
Operating Cash Flow Yield
29.09%
TTM Avg
26.97%
3Y Avg
26.97%
5Y Avg
26.97%
Market Cap
$97.27M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$97.18M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| electroCore, Inc. (ECOR) | $93.22M | N/A | N/A | N/A | N/A |
| Biomea Fusion, Inc. (BMEA)vs › | $93.63M | N/A | N/A | N/A | N/A |
| Park Dental Partners, Inc. Common Stock (PARK)vs › | $93.80M | 10367.13% | 3068.81% | 3068.81% | 3068.81% |
| Neumora Therapeutics, Inc. Common Stock (NMRA)vs › | $91.83M | N/A | N/A | N/A | N/A |
| Equillium, Inc. (EQ)vs › | $90.73M | N/A | 23.25% | 23.25% | 23.25% |
| PMV Pharmaceuticals, Inc. (PMVP)vs › | $89.86M | N/A | N/A | N/A | N/A |
| Rallybio Corporation (RLYB)vs › | $90.54M | 29.09% | 26.97% | 26.97% | 26.97% |
| Conexeu Sciences Inc. (CNXU)vs › | $97.27M | N/A | N/A | N/A | N/A |
| Milestone Pharmaceuticals Inc. (MIST)vs › | $97.18M | N/A | N/A | N/A | N/A |
| ImmuCell Corporation (ICCC)vs › | $88.48M | 6.66% | 4.42% | 3.83% | 2.85% |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
